In a meta-analysis of 10 studies, topiroxostat significantly improved the estimated glomerular filtration rate (eGFR) and reduced the urinary albumin/creatinine ratio (UACR) compared to the placebo in patients with CKD [9]. Here, ALB is linked to chronic kidney disease.